Isofol Medical AB was founded in 2008 based on the research of Professor Bengt Gustavsson and his collaboration with Merck & Cie, the world’s leading manufacturer of folate-based therapies. Isofol’s main objective is to improve the outlook for the majority of cancer patients undergoing chemotherapy treatments.

Isofol’s clinical lead candidate is Modufolin®, a novel folate-based therapy developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-based drugs today and therefore does not require metabolic activation to exert its action.

Isofol intends to take Modufolin® to market registration through a couple of clinical trials. Isofol will then follow the most favourable strategy to commercialise Modufolin® worldwide.